Well, todays subject isnt a cheerful data set, but it certainly deserves some thought. Over at Pharmalot, Ed Silverman has some data from consulting firm AVOS Life Sciences, who have sat down to estimate how well various drug companies will do with revenue from new drugs over the next few years. As of 2007, they have the industry average at about 77 cents coming from new products (defined as those launched within the previous five...